BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6362907)

  • 1. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.
    Van de Werf F; Bergmann SR; Fox KA; de Geest H; Hoyng CF; Sobel BE; Collen D
    Circulation; 1984 Mar; 69(3):605-10. PubMed ID: 6362907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronary thrombolysis in dogs with intravenously administered human pro-urokinase.
    Collen D; Stump D; van de Werf F; Jang IK; Nobuhara M; Lijnen HR
    Circulation; 1985 Aug; 72(2):384-8. PubMed ID: 3924437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA; Gold HK; Yasuda T; Kanke M; Guerrero JL; Fallon JT; Saito T; Collen D
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
    Gold HK; Fallon JT; Yasuda T; Leinbach RC; Khaw BA; Newell JB; Guerrero JL; Vislosky FM; Hoyng CF; Grossbard E
    Circulation; 1984 Oct; 70(4):700-7. PubMed ID: 6541103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
    Van de Werf F; Jang IK; Collen D
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
    Söhngen W; Mickelson JK; Simpson PJ; Lucchesi BR
    Thromb Res; 1988 Jul; 51(1):63-74. PubMed ID: 3137691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
    Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.
    Flameng W; Van de Werf F; Vanhaecke J; Verstraete M; Collen D
    J Clin Invest; 1985 Jan; 75(1):84-90. PubMed ID: 4038406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
    Flameng W; Vanhaecke J; Stump DC; Van de Werf F; Holmes W; Guenzler WA; Flohe L; Collen D
    J Am Coll Cardiol; 1986 Jul; 8(1):118-24. PubMed ID: 3086416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
    Chen LY; Nichols WW; Saldeen TG; Mehta JL
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of coronary thrombolysis with plasminogen pro-activator by pretreatment with heparin.
    Susawa T; Yui Y; Hattori R; Takatsu Y; Yui N; Takahashi M; Aoyama T; Murohara Y; Shirotani M; Kawai C
    Jpn Circ J; 1988 Jan; 52(1):72-8. PubMed ID: 3129601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin requirement in tissue-type plasminogen activator-induced experimental coronary thrombolysis: comparison with urokinase-induced coronary thrombolysis.
    Susawa T; Yui Y; Hattori R; Takahashi M; Aoyama T; Takatsu Y; Sakaguchi K; Yui N; Kawai C
    Jpn Circ J; 1987 Apr; 51(4):431-5. PubMed ID: 2441082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
    Yokoyama M; Ichikawa Y; Yatani A; Matsui K; Nakahara H; Kaneko M; Sakurama T; Ueshima S; Matsuo O
    J Cardiovasc Pharmacol; 1996 Oct; 28(4):571-5. PubMed ID: 8891884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrograde coronary venous administration of recombinant tissue-type plasminogen activator: a unique and effective approach to coronary artery thrombolysis.
    Miyazaki A; Tadokoro H; Drury JK; Rydén L; Haendchen RV; Corday E
    J Am Coll Cardiol; 1991 Aug; 18(2):613-20. PubMed ID: 1906906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
    Yasuda T; Gold HK; Fallon JT; Leinbach RC; Garabedian HD; Guerrero JL; Collen D
    J Am Coll Cardiol; 1989 May; 13(6):1409-14. PubMed ID: 2495318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indications for and limitations of coronary thrombolysis.
    Kanmatsuse K; Kajiwara N; Onikura S; Satoh Y; Andoh T
    Jpn Circ J; 1985 Jun; 49(6):597-604. PubMed ID: 3162042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
    Spriggs DJ; Stassen JM; Hashimoto Y; Collen D
    Blood; 1989 Apr; 73(5):1207-12. PubMed ID: 2495034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.